Results 91 to 100 of about 32,295 (302)
, 2001 The treatment of schizophrenic patients who fail to respond to adequate trials of neuroleptic drugs is a major challenge. Clozapine has been one treatment option; however, it is not universally effective and is limited in its use by safety concerns. With
Birkett, M.A. +3 more
core +1 more source
Addiction, EarlyView.Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens +7 more
wiley +1 more source
Frontiers in Psychiatry, 2017 The authors present the case of a 24-year-old male with treatment-resistant schizophrenia, with predominant severe delusion and hallucination, who received bone marrow transplantation (BMT) for acute myeloid leukemia.
Tsuyoshi Miyaoka +11 more
doaj +1 more source
Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева, 2018 The article provides an overview of data in the literature devoted to the combined use of electroconvulsive therapy (ECT) and antipsychotics in treatment of resistant schizophrenia. ECT with anesthesia and muscle relaxants is a fairly safe method.
S. V. Sizov, Y. B. Barylnik
doaj
Frontiers in PsychiatryBackgroundTreatment resistance in schizophrenia is a major clinical challenge. While autistic traits are often more pronounced in patients with treatment-resistant schizophrenia (TRS), limited data exist on clozapine-resistant schizophrenia (CRS).
Ahmet Selim Başaran +3 more
doaj +1 more source
Acta Paediatrica, EarlyView.ABSTRACT Aim To explore changes in body composition in adolescents with obesity treated with glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) and their association with metabolic syndrome (MetS) components. Methods This real‐world retrospective study included adolescents (12–18 years) with obesity who received multidisciplinary lifestyle‐based ...
Adar Lopez +11 more
wiley +1 more source
British Journal of Clinical Psychology, EarlyView.Abstract Objectives To synthesize current evidence and provide clinically actionable recommendations for integrating menstrual cycle‐related processes—particularly hormone sensitivity, Premenstrual Dysphoric Disorder (PMDD) and Premenstrual Exacerbation (PME)—into psychological assessment, formulation and treatment.
Ellen R. Lambert +2 more
wiley +1 more source
, 2017 Background: This is a retrospective case–control study with an aim to explore the pattern and predictors of treatment-resistant schizophrenia with a large cohort of first-episode psychosis patients with more than 12 years of illness duration.
Chan, KWS, Chang, WC, Sham, PC
core +1 more source
Table_1_Treatment-resistant schizophrenia: How far have we traveled?.DOCX
, 2022 Treatment-resistant schizophrenia is a lack of adequate response to antipsychotic medications resulting in incomplete functional and social recovery from the illness.
Kamal Narayan Kalita (13520983) +1 more
core +1 more source
Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?
British Journal of Pharmacology, EarlyView.Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli +7 more
wiley +1 more source